Abstract
Background
The present study was conducted with the aim of investigating the prevalence of potentially beneficial and harmful drug-drug interactions (DDIs) in intensive care units (ICUs).
Methods
The present cross-sectional prospective study was conducted in two ICUs in Shahr-e Kord city, Iran. The study sample was consisted of 300 patients. The Drug Interaction Facts reference text book [Tatro DS. Drug interaction facts. St Louis, MO: Walters Kluwer Health, 2010.] was used to determine the type and the frequency of the DDIs.
Results
The participants consisted of 189 patients men and 111 women. The mean age of patients was 44.2 ± 24.6 years. Totally, 60.5% of patients had at least one drug-drug interaction in their profile. The total number of DDIs found was 663 (the mean of the total number of drug-drug interactions was 2.4 interactions per patient). Of all the 663 interactions, 574 were harmful and others were beneficial. In terms of starting time, 98 of the potential interactions were rapid and 565 of them were delayed. In terms of severity, 511 of the potential interactions were moderate. Some of the drugs in the patients’ medical records including phenytoin, dopamine, ranitidine, corticosteroid, dopamine, heparin, midazolam, aspirin, magnesium, calcium gluconate, and antibiotics, the type of ventilation, the type of nutrition and the duration of hospital stay were among the factors that were associated with high risk of potential DDIs (p < 0.05).
Conclusions
The prevalence of potentially beneficial and harmful DDIs, especially harmful drug-drug interactions, is high in ICUs and it is necessary to reduce these interactions by implementing appropriate programs and interventions.
Acknowledgments
The authors would like to thank and appreciate the research and technology department of Shahr-e Kord University of Medical Sciences as well as ICU head nurses and nurses for their cooperation in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
[1] Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva 2015;27:353–9.10.5935/0103-507X.20150060Search in Google Scholar PubMed PubMed Central
[2] Loj P, Olender A, Slezak W, Krzych LJ. Pharmacokinetic drug-drug interactions in the intensive care unit – single-centre experience and literature review. Anaesthesiol Intensive Therapy 2017;49:259–67.Search in Google Scholar
[3] Pejčić AV, Janković SM, Davidović G. Drug-drug interactions in patients with acute coronary syndrome across phases of treatment. Intern Emerg Med. 2018;27:1–12.10.1007/s11739-018-1994-8Search in Google Scholar PubMed
[4] Hernandez M, Tribino G, Bustamante C. Characterization of potential drug-drug interactions in patients hospitalized in the intensive care unit of a tertiary hospital in Bogota. Biomedica 2018;38:407–16.Search in Google Scholar
[5] Hasnain H, Ali H, Zafar F, Sial AA, Alam S, Beg AE, et al. Incidence of drug interactions in intensive care units in tertiary care settings: classification, facts and measures. Pakistan J Pharm Sci 2018;31(Suppl.):669–75.Search in Google Scholar
[6] Hassanzad M, Arenas-Lopez S, Baniasadi S. Potential drug-drug interactions among critically ill pediatric patients in a tertiary pulmonary center. J Clin Pharmacol 2018;58:221–7.10.1002/jcph.996Search in Google Scholar PubMed
[7] Ismail M, Khan F, Noor S, Haider I, Haq IU, Ali Z, et al. Potential drug-drug interactions in medical intensive care unit of a tertiary care hospital in Pakistan. Internat J Clin Pharmacy 2016;38:1052–6.10.1007/s11096-016-0340-3Search in Google Scholar PubMed
[8] Gulcebi Idriz Oglu M, Kucukibrahimoglu E, Karaalp A, Sarikaya O, Demirkapu M, Onat F, et al. Potential drug-drug interactions in a medical intensive care unit of a university hospital. Turk J Med Sci 2016;46:812–9.10.3906/sag-1504-147Search in Google Scholar PubMed
[9] Makiani MJ, Nasiripour S, Hosseini M, Mahbubi A. Drug-drug interactions: the importance of medication reconciliation. J Res Pharmacy Practice 2017;6:61–2.10.4103/2279-042X.200992Search in Google Scholar PubMed PubMed Central
[10] Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Invest 2011;31:309–16.10.1007/BF03256929Search in Google Scholar PubMed
[11] Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Internat J Clin Pharmacol Therapeutics 2000;38:504–13.10.5414/CPP38504Search in Google Scholar PubMed
[12] Jankovic SM, Pejcic AV, Milosavljevic MN, Opancina VD, Pesic NV, Nedeljkovic TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care 2018;43:1–6.10.1016/j.jcrc.2017.08.021Search in Google Scholar PubMed
[13] Vanham D, Spinewine A, Hantson P, Wittebole X, Wouters D, Sneyers B. Drug-drug interactions in the intensive care unit: do they really matter? J Crit Care 2017;38:97–103.10.1016/j.jcrc.2016.09.014Search in Google Scholar PubMed
[14] Gupta M, Chincholkar AS, Wagh RJ, Maheshwari N, Siddiqui W. A study of potential drug-drug interactions among critically ill patients at a tertiary care hospital. Int J Basic Clin Pharmacol 2017;5:5.10.18203/2319-2003.ijbcp20161899Search in Google Scholar
[15] Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo) 2011;66:9–15.10.1590/S1807-59322011000100003Search in Google Scholar
[16] Tatro DS. Drug interaction facts. St Louis, MO: Walters Kluwer Health, 2010.Search in Google Scholar
[17] Rosas-Carrasco O, Garcia-Pena C, Sanchez-Garcia S, Vargas-Alarcon G, Gutierrez-Robledo LM, Juarez-Cedillo T. The relationship between potential drug-drug interactions and mortality rate of elderly hospitalized patients. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2011;63:564–73.Search in Google Scholar
[18] Rafiei H, Abdar ME, Amiri M, Ahmadinejad M. The study of harmful and beneficial drug interactions in intensive care, Kerman, Iran. J Intensive Care Soc 2013;14:155–8.10.1177/175114371301400214Search in Google Scholar
[19] Khandeparkar A, Rataboli PV. A study of harmful drug-drug interactions due to polypharmacy in hospitalized patients in Goa Medical College. Perspect Clin Res 2017;8:180–6.10.4103/picr.PICR_132_16Search in Google Scholar PubMed PubMed Central
[20] Valizade Hasanloei M, Sharifi H, Hasanzadeh A. Drug-drug interactions prevalence in intensive care unit patients of a university hospital in Iran. Bull Env Pharmacol Life Sci 2014;3:87–91Search in Google Scholar
[21] Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharmacy Pharmaceutical Sci 2009;12:266–72.10.18433/J35C7ZSearch in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston
